Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Glaukos Corporation Common Stock
(NY:
GKOS
)
114.34
+1.07 (+0.94%)
Streaming Delayed Price
Updated: 10:56 AM EST, Feb 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Glaukos Corporation Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Glaukos (GKOS) Q2 Revenue Jumps 30%
↗
August 01, 2025
Via
The Motley Fool
Glaukos Announces Second Quarter 2025 Financial Results
July 30, 2025
From
Glaukos Corporation
Via
Business Wire
Earnings Scheduled For July 30, 2025
↗
July 30, 2025
Via
Benzinga
Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30
July 09, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies
June 25, 2025
From
Glaukos Corporation
Via
Business Wire
Earnings Scheduled For April 30, 2025
↗
April 30, 2025
Via
Benzinga
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today
↗
February 24, 2025
Via
Benzinga
Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell
June 25, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in Upcoming Investor Conferences
May 13, 2025
From
Glaukos Corporation
Via
Business Wire
What 11 Analyst Ratings Have To Say About Glaukos
↗
May 02, 2025
Via
Benzinga
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
↗
May 01, 2025
Via
Benzinga
Earnings Scheduled For February 20, 2025
↗
February 20, 2025
Via
Benzinga
Peering Into Glaukos's Recent Short Interest
↗
February 12, 2025
Via
Benzinga
How Is The Market Feeling About Glaukos?
↗
January 27, 2025
Via
Benzinga
$1000 Invested In Glaukos 5 Years Ago Would Be Worth This Much Today
↗
January 23, 2025
Via
Benzinga
Glaukos Announces First Quarter 2025 Financial Results
April 30, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
April 23, 2025
From
Glaukos Corporation
Via
Business Wire
Forecasting The Future: 7 Analyst Projections For Glaukos
↗
April 16, 2025
Via
Benzinga
Glaukos Announces the Release of its 2024 Sustainability Report
April 16, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30
April 09, 2025
From
Glaukos Corporation
Via
Business Wire
Here's How Much You Would Have Made Owning Glaukos Stock In The Last 5 Years
↗
March 28, 2025
Via
Benzinga
RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution
March 11, 2025
From
Glaukos Corporation
Via
Business Wire
FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery
↗
February 24, 2025
Glaukos' Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its non-invasive treatment potential.
Via
Benzinga
Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™
February 24, 2025
From
Glaukos Corporation
Via
Business Wire
Consumer Sentiment Drops 10%, UnitedHealth Under Investigation: What's Driving Markets Friday?
↗
February 21, 2025
All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about the economic outlook.
Via
Benzinga
Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition
↗
February 21, 2025
Glaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as the company expands its business model.
Via
Benzinga
Wondering what's happening in today's after-hours session?
↗
February 20, 2025
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via
Chartmill
Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results
February 20, 2025
From
Glaukos Corporation
Via
Business Wire
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
↗
February 19, 2025
Via
Benzinga
Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20
January 23, 2025
From
Glaukos Corporation
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
